Clinical trials: Cell Transplantation
Stem Cell Transplant Complications
Loratadine for the Prevention of G-CSF-related Bone Pain
The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma?…
- Trial name
- NCT05421416
- Testing
- Loratadine
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- AHS Cancer Control Alberta
Myeloma, Multiple, Paraproteinemias
Comprehensive Frailty Assessment
The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health.
- Conditions
- Myeloma, Multiple, Paraproteinemias, Hematologic Neoplasms
- Trial name
- NCT02033928
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lupus Nephritis
Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis
In this study, we aimed to evaluate the long term efficacy, remission, survival and safety of autologous hematopoietic stem cell transplantation in patients with refractory lupus nephritis.
- Trial name
- NCT03828071
- Testing
- Autologous hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Nanjing University School of Medicine
Kidney Transplantation, Cytomegalovirus Infections
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
Kidney transplant patients under an immunosuppressive treatment based on anti-calcineurin and mycophenolate-mofetil and induction therapy with rATG who suffer from early systemic viral replication by the CMV virus could benefit…
- Trial name
- ACTIVA (NCT04936971)
- Testing
- Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm, no intervention
- Where
- Spain
- Sponsor
- Edoardo Melilli
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
This phase II trial investigates side effects and how well donor stem cell transplant after chemotherapy works in treating pediatric and adolescent-young adults with high-risk solid tumor that has come back (recurrent) or does…
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor
- Trial name
- NCT04530487
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy
- Trial name
- FLAT-Auto (NCT03961919)
- Testing
- Fludarabine, ARA-C, Treosulfan
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ciceri Fabio
Multiple Myeloma
Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma
This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and feasible to administer after ASCT in…
- Trial name
- NCT03173430
- Testing
- Blinatumomab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
AML, AML (Acute Myeloid Leukemia)
Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute…
- Trial name
- NCT07342244
- Testing
- CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Donghua Zhang
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
The goal of this clinical trial is to evaluate clinical efficacy of incorporating Epcoritamab into the salvage treatment routine for relapsed-refractory aggressive B-cell lymphoma, followed by autologous stem-cell transplantation…
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, DLBCL, Nos Genetic Subtypes
- Trial name
- NCT06287398
- Testing
- Epcoritamab
- Where
- Australia
- Volunteers
- 39 people
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stem Cell Transplant, Late Effect
Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT
Today the overall survival of childhood cancers has increased to above 85%. This increase is partially caused by treatment with bone marrow transplantation.
- Conditions
- Stem Cell Transplant, Late Effect, Neurocognitive Dysfunction, Paediatric Patients
- Trial name
- MindMe (NCT07140445)
- Where
- Denmark
- Volunteers
- 175 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, EBV
A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT
To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem…
- Conditions
- CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, EBV, Hemophagocytic Lymphohistiocytoses
- Trial name
- NCT06491719
- Testing
- NCR300（Allogenic Ipsc-derived Natural Killer cells ）
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Friendship Hospital
Cytomegalovirus (CMV)
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after…
- Trial name
- NCT02927067
- Testing
- Maribavir, Valganciclovir
- Where
- 129 sites in United States, Australia and 21 more
- Volunteers
- 553 people
- Sponsor
- Shire
Acute Leukemia, Hematologic and Lymphocytic Disorder
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
This phase IIa trial studies the side effects of itacitinib when given together with standard treatment (tacrolimus and sirolimus), and to see how well it works in preventing graft-versus-host-disease (GVHD) in patients with…
- Conditions
- Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis
- Trial name
- NCT04339101
- Testing
- Fludarabine, Itacitinib Adipate, Melphalan
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- City of Hope Medical Center
Osteochondritis of the Femoral Head
Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head
Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties. Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to MSCs.
- Trial name
- NCT00813267
- Testing
- mesenchymal stem cell infusion, bone marrow mononuclear cell infusion
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Jianming Tan
Vasculopathy, Heart Transplant Failure
The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients
Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients.
- Trial name
- NCT05485467
- Testing
- coronary CT angiography
- Where
- Slovenia
- Volunteers
- 55 people
- Sponsor
- University Medical Centre Ljubljana
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM).
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00006244
- Testing
- melphalan, recombinant interferon alfa, aldesleukin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Plasma Cell Myeloma
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant.
- Trial name
- NCT03622775
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Leukemia, Myelodysplastic Syndrome
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
RATIONALE: Conditioning with total body irradiation (TBI) and fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic…
- Conditions
- Acute Leukemia, Myelodysplastic Syndrome, Solid Tumors
- Trial name
- NCT01509300
- Testing
- anti-thymocyte globulin, filgrastim, Total body irradiation
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Asan Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.